Servier

US, EU regulators start swift reviews of Servier glioma drug
Pharmaphorum
Wed, 02/21/24 - 11:09 am
FDA
EMA
Servier
vorasidenib
glioma
brain cancer
Servier’s vorasidenib proves efficacy in tumor growth reduction
Clinical Trials Arena
Mon, 11/20/23 - 10:09 am
Servier
vorasidenib
glioma
clinical trials
Servier’s Tibsovo Gets FDA Approval as First Targeted Therapy for MDS
BioSpace
Wed, 10/25/23 - 09:41 am
Servier
Tibsovo
MDS
FDA
FDA starts speedy review of Servier's Tibsovo in MDS
Pharmaphorum
Thu, 08/17/23 - 09:58 am
Servier
IDH inhibitors
MDS
Tibsovo
FDA
priority reviews
ASCO: French Pharma's Drug Slows Tumors in Brain Cancer Patients
BioSpace
Mon, 06/5/23 - 10:00 pm
ASCO 2023
Servier
glioma
vorasidenib
Servier adds a 'smile' to its brand while setting ambitious oncology goals
Endpoints
Sun, 10/9/22 - 05:55 pm
Servier
corporate branding
ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe
Fierce Pharma
Sat, 12/11/21 - 09:15 pm
ASH2021
Servier
Tibsovo
AML
Servier Phase III colorectal cancer trial fails to meet primary endpoint
Pharmafile
Sun, 10/24/21 - 10:36 pm
Servier
colorectal cancer
clinical trials
Lonsurf
Servier cans autism hope bumetanide after phase 3 fails
Pharmaforum
Tue, 09/7/21 - 10:45 pm
Servier
Neurochlore
autism
autism spectrum disorder
bumetanide
clinical trials
With fresh FDA nod, Servier branches targeted drug Tibsovo into bile duct cancer
Fierce Pharma
Fri, 08/27/21 - 10:44 am
Servier
Tibsovo
bile duct cancer
FDA
Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal
Pharmaforum
Mon, 08/2/21 - 09:39 pm
Servier
Agios
M&A
Tibsovo
AML
Precision reacquires rights to allogeneic CAR-Ts from Servier
Fierce Biotech
Fri, 04/16/21 - 09:58 am
Precision Biosciences
allogeneic cells
CAR-T
Servier
Agios, changing its identity, to sell cancer drug business to Servier
BioPharma Dive
Mon, 12/21/20 - 11:11 am
Agios Pharmaceuticals
cancer
M&A
Servier
Colorectal drug candidates focal point of new collaboration between Servier, Celsius Therapeutics
Endpoints
Mon, 12/21/20 - 10:56 am
Servier
Celsius Therapeutics
colorectal cancer
drug discovery
Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal
Fierce Biotech
Fri, 10/16/20 - 11:11 am
Galapagos
Servier
GLPG1972
osteoarthritis of the knee
clinical trials
Amgen and Cytokinetics claim heart drug success, but results widely disappoint
BioPharma Dive
Thu, 10/8/20 - 11:19 pm
Amgen
Cytokinetics
Servier
clinical trials
Omecamtiv Mecarbil
cardiovascular disease
Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
AP
Fri, 04/3/20 - 12:27 pm
Servier
R&D
Symphogen
antibodies
Trial of Amgen, Servier’s heart failure drug clears interim check
PM Live
Fri, 02/28/20 - 10:18 am
Amgen
Servier
chronic heart failure
Omecamtiv Mecarbil
clinical trials
Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier
Endpoints
Wed, 02/19/20 - 09:56 am
CAR-T
Cellectis
Servier
UCART19
Servier reveal how they are using data to empower their field force
Pharmaforum
Tue, 11/12/19 - 10:16 am
Servier
drug reps
CRM
digital pharma

Pages